Literature DB >> 16496225

Mini-dystrophin efficiently incorporates into the dystrophin protein complex in living cells.

Romesh A Draviam1, Bing Wang, Juan Li, Xiao Xiao, Simon C Watkins.   

Abstract

Dystrophin is a critical muscle cell structural protein which when deficient results in Duchenne muscular dystrophy. Recently miniature versions of the dystrophin gene have been constructed that ameliorate the pathology in mouse models. To characterize mini-dystrophin's incorporation into the dystrophin protein complex in living cells, two fusion proteins were constructed where mini-dystrophin is fused to the N- or C-terminus of an enhanced green fluorescent protein reporter gene. Both fusion proteins correctly localize at the plasma membrane in vitro and in vivo. Live cell microscopy establishes that mini-dystrophin translocates directly to the PM of differentiating muscle cells, within 4 h of expression. Latrunculin A treatment, actin and beta-dystroglycan binding domain deletion constructs, and co-immunoprecipitation assays demonstrate that mini-dystrophin is firmly anchored to the sarcolemma primarily through its connections to beta-dystroglycan, mimicking effects seen with wild type dystrophin. Furthermore, point mutations made within the putative beta-dystroglycan anchoring ZZ domain of mini-dystrophin result in an ablation of beta-dystroglycan binding and a nuclear translocation of the protein. These results demonstrate that mini-dystrophin is efficiently bound and incorporated into the dystrophin protein complex, via beta-dystroglycan in living cells, similarly to the full length dystrophin protein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16496225     DOI: 10.1007/s10974-006-9055-8

Source DB:  PubMed          Journal:  J Muscle Res Cell Motil        ISSN: 0142-4319            Impact factor:   2.698


  58 in total

1.  Latrunculin alters the actin-monomer subunit interface to prevent polymerization.

Authors:  W M Morton; K R Ayscough; P J McLaughlin
Journal:  Nat Cell Biol       Date:  2000-06       Impact factor: 28.824

2.  A-kinase-interacting protein localizes protein kinase A in the nucleus.

Authors:  Mira Sastri; David M Barraclough; Peter T Carmichael; Susan S Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-03       Impact factor: 11.205

3.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy.

Authors:  X Xiao; J Li; Y P Tsao; D Dressman; E P Hoffman; J F Watchko
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 5.  Dystrophin abnormalities in Duchenne/Becker muscular dystrophy.

Authors:  E P Hoffman; L M Kunkel
Journal:  Neuron       Date:  1989-01       Impact factor: 17.173

6.  Immunoelectron microscopic localization of dystrophin in myofibres.

Authors:  S C Watkins; E P Hoffman; H S Slayter; L M Kunkel
Journal:  Nature       Date:  1988-06-30       Impact factor: 49.962

7.  Dystroglycan is not required for localization of dystrophin, syntrophin, and neuronal nitric-oxide synthase at the sarcolemma but regulates integrin alpha 7B expression and caveolin-3 distribution.

Authors:  Patrice D Côté; Hakima Moukhles; Salvatore Carbonetto
Journal:  J Biol Chem       Date:  2001-12-06       Impact factor: 5.157

8.  The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers.

Authors:  R Pruchnic; B Cao; Z Q Peterson; X Xiao; J Li; R J Samulski; M Epperly; J Huard
Journal:  Hum Gene Ther       Date:  2000-03-01       Impact factor: 5.695

9.  Formation of multiple complexes between beta-dystroglycan and dystrophin family products.

Authors:  M Royuela; D Chazalette; G Hugon; R Paniagua; V Guerlavais; J A Fehrentz; J Martinez; J P Labbe; F Rivier; D Mornet
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

10.  Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene.

Authors:  Miki Sakamoto; Katsutoshi Yuasa; Madoka Yoshimura; Toshifumi Yokota; Takaaki Ikemoto; Misao Suzuki; George Dickson; Yuko Miyagoe-Suzuki; Shin'ichi Takeda
Journal:  Biochem Biophys Res Commun       Date:  2002-05-17       Impact factor: 3.575

View more
  3 in total

1.  CRISPR-Induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In Vitro and In Vivo.

Authors:  Benjamin L Duchêne; Khadija Cherif; Jean-Paul Iyombe-Engembe; Antoine Guyon; Joel Rousseau; Dominique L Ouellet; Xavier Barbeau; Patrick Lague; Jacques P Tremblay
Journal:  Mol Ther       Date:  2018-08-16       Impact factor: 11.454

2.  Phosphorylation within the cysteine-rich region of dystrophin enhances its association with β-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting.

Authors:  Kristy Swiderski; Scott A Shaffer; Byron Gallis; Guy L Odom; Andrea L Arnett; J Scott Edgar; Dale M Baum; Annabel Chee; Timur Naim; Paul Gregorevic; Kate T Murphy; James Moody; David R Goodlett; Gordon S Lynch; Jeffrey S Chamberlain
Journal:  Hum Mol Genet       Date:  2014-07-31       Impact factor: 6.150

3.  The ZZ domain of dystrophin in DMD: making sense of missense mutations.

Authors:  Adeline Vulin; Nicolas Wein; Dana M Strandjord; Eric K Johnson; Andrew R Findlay; Baijayanta Maiti; Michael T Howard; Yuuki J Kaminoh; Laura E Taylor; Tabatha R Simmons; Will C Ray; Federica Montanaro; Jim M Ervasti; Kevin M Flanigan
Journal:  Hum Mutat       Date:  2013-12-02       Impact factor: 4.878

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.